Skip to content
Screener

Ashland ASH Specialty Additives — Research And Development Expense

Other segment segments

Personal Care And Household
$6M0.0%
Unallocated And Other
$1M
Intermediates And Solvents
$0

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Research And Development Expense
$5.99M-1.2%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Church & Dwight logo
CHDSpecialty Products Division — Research And Development Expense
$800K+33.3%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Helios Technologies logo
HLIOUnallocated Expenses — Research And Development Expense
$0

Other financials

Income statement

See full
Revenue$497.0M+7.3%
Gross profit$170.0M+28.8%
Operating income$43.0M+106%
Net income$16.0M+102%
EPS (diluted)$0.35+102%

Balance sheet

See full
Cash & equivalents$440.0M+113%
Total debt$1.5B-0.6%
Total equity$1.9B-1.0%
Total assets$4.6B-0.9%

Cash flow

See full
Operating cash flow$120.0M+4.3%
CapEx$20.0M0.0%
Free cash flow$100.0M+5.3%

Valuation

See full
Market cap$3.32B+40.6%
Enterprise value$4.35B+19.7%
P/E165.9×
P/S1.8×+0.5×

Profitability

See full
Gross margin31.5%+1.4pp
Operating margin4.1%
Net margin1.1%+0.5pp
FCF margin13.6%+9.7pp

Returns & leverage

See full
Return on equity1.1%+0.5pp
Debt / equity0.8×0.0×
Current ratio+0.4×

Where this comes from

Reported directly by Ashland in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Ashland’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:17 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324226
(In millions - unaudited)Three months ended / June 30 / 2026Three months ended / June 30 / 2025Nine months ended / June 30 / 2026Nine months ended / June 30 / 2025
Research and development expense
Life Sciences$4$4$11$12
Personal Care661719
Specialty Additives43108
Intermediates1
Total operating segments14133939
Unallocated and other122
$15$13$41$41

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ashland's specialty additives — research and development expense?
Ashland (ASH) reported specialty additives — research and development expense of $4M in Q2 2026.
How has Ashland's specialty additives — research and development expense changed year-over-year?
Ashland's specialty additives — research and development expense increased by 33.3% year-over-year, from $3M to $4M.
What is the long-term trend for Ashland's specialty additives — research and development expense?
Over 2 years (2023 to 2025), Ashland's specialty additives — research and development expense has grown at a 8.7% compound annual growth rate (CAGR), from $11M to $13M.
What does specialty additives — research and development expense mean?
This represents the investment in innovation, product development, and technical improvements within the specialty additives segment. It reflects the company's commitment to maintaining a competitive edge through new product launches and process enhancements. High levels of R&D spending are typically viewed as a strategic investment for long-term growth and market differentiation.

Ask your AI about Ashland's specialty additives — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude